Search

everythinglearnresearchcommunity

for

Search:↓

Certain metabolites are lower in women with PCOS and could be potential markers for the condition.

Hidradenitis suppurativa may be related to hormones and patients often have metabolic disorders; more research is needed to understand this connection.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Women with PCOS have a higher risk of diabetes, heart problems, certain cancers, and mental health issues, but early treatment can help manage these risks.

Hair loss in women not always linked to increased oil production; other factors may be involved.

The research found different metabolism changes in PCOS patients and suggested new potential markers for diagnosing PCOS with or without insulin resistance.

Finasteride may help some women with hair loss, but better options exist.

Women with PCOS have higher levels of certain blood clotting factors, suggesting a greater risk of cardiovascular issues.

Ovarian SAHA syndrome makes women with PCOS more resistant to insulin and increases their risk of blood sugar problems.

Women with PCOS have unhealthy changes in their cholesterol particles that are not related to their body weight.

Hirsute women have lower type 2 17β-HSD enzyme levels, which improve with treatment.

Menopausal women have higher androgen levels, which can cause symptoms like facial hair growth and low sexual desire.

Certain SHBG gene variants, like rs727428, are linked to higher testosterone levels in women with PCOS.

Women with hyperandrogenic amenorrhea have similar bone density to healthy women but lower than androgenized women without amenorrhea, and high DHEAS levels might affect bone density.

Larger ovarian size is linked to higher insulin resistance in women with PCOS.

The document concludes that there are no reliable treatments for frontal fibrosing alopecia, with only temporary benefits from current options.

Measuring the distance from the anus to the clitoris may moderately help diagnose polycystic ovary syndrome, especially in certain cases.

Parathyroid hormones are important for hair growth, but their use in treating hair loss from chemotherapy is still uncertain.

Women with polycystic ovary syndrome have a higher risk of certain fractures.

Skin diseases linked to insulin resistance should be managed to prevent diabetes and reduce heart disease risk.

Finasteride 2.5 mg/day can effectively treat female hair loss.

EF and PXE not closely related.

Hair loss in women can be slowed with treatment, but more research needed for better solutions.

Young women with nonclassic congenital adrenal hyperplasia may experience worse sexual function and mild depression compared to healthy women.

Finasteride 1.25 mg showed small improvements in hair density and thickness for female pattern hair loss, but more research is needed.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

Antiandrogens are the main treatment for hirsutism, with individualized care and safe, affordable options needed.

Hirsutism in women is often due to hormone sensitivity and has significant psychological effects.

This text talks about how to treat hair loss in women. It suggests different options and stresses the importance of support.

Ovarian Leydig cell tumors are hard to diagnose with just advanced imaging; expert ultrasound and clinical evaluation are essential.